they are justifying why he would want to leave I bet none...

they are justifying why he would want to leave

I bet none mentioned his option package got knocked back

or that pax performs better than the standard of care

or that we are in 8 trials with Pax

or that the only reason it’s not progressing to stage 2 in Agile trial is because it didn’t meet some super high benchmark > No other drug has yet obtained…

whilst still performing better than the standard of care.

agile data will underwrite our FDA application this year

we have a shot at a PRV

we have 42 mill in milestone payments should Cantrixil proceed

we are still the most exciting drug in small biotech and with new trials opening up

we will get to the end and be approved it’s just the path we take

the issue before was great results not enough patients - we will soon have 150 more patients from our arm plus the 300 in the control arm plus 120+ from previous trials

ANP seems interesting and if James is interested to be there it’s worth a look - but it’s no Kazia/Paxalisib it’s maybe an interesting 2nd